OTC: TLPPF - Telix Pharmaceuticals Limited

Rentabilité sur six mois: +64.02%
Secteur: Healthcare

Calendrier des promotions Telix Pharmaceuticals Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR.

Plus de détails
Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

EBITDA -0.0349
EV/EBITDA -7.99
Industry Biotechnology
P/BV 3.4
P/E 609.87
P/S 68.32
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.005
Сайт https://telixpharma.com
Цена ао 8.69
Число акций ао 0.32371 млрд
Changement de prix par jour: 0% (14.475)
Changement de prix par semaine: +3.39% (14)
Changement de prix par mois: +13.17% (12.79)
Changement de prix sur 3 mois: +12.04% (12.92)
Changement de prix sur six mois: +64.02% (8.825)
Changement de prix par an: +120.32% (6.57)
Evolution du prix sur 3 ans: +221.67% (4.5)
Evolution des prix depuis le début de l'année: +154.84% (5.68)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 6.32 1
P/BV 14.34 1
P/E 609.87 1
EV/EBITDA 51.61 1
Total: 2.13

Efficacité

Nom Signification Grade
ROA, % 0.8845 1
ROE, % 2.39 1
Total: 2.33

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0.2457 10
Total: 9

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 10459.38 10
Rentabilité Ebitda, % -275.45 0
Rentabilité EPS, % -109.9 0
Total: 2
Plus de détails

Établissements Volume Partager, %
Vanguard International Stock Index-Total Intl Stock Indx 2270925 0.7
iShares Core MSCI EAFE ETF 1376002 0.42
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1343237 0.41
College Retirement Equities Fund-Stock Account 937783 0.29
iShares MSCI EAFE Small Cap ETF 923323 0.28
TIAA-CREF Funds-Quant International Small Cap Equity Fund 706384 0.22
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 619774 0.19
SPDR Portfolio Developed World ex-US ETF 468831 0.14
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 323859 0.1
iShares Core MSCI Total International Stock ETF 312675 0.1



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 379.52k 1965 (59 années)
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Non-Executive Director 28.57k 1965 (59 années)
Mr. Richard Valeix M.B.A. Chief Executive Officer of Telix Therapeutics 424.25k 1975 (49 années)
Mr. Craig Ulrick Chief Information Officer N/A
Ms. Kyahn Williamson B.A. Senior Vice President of Corporate Communications & Investor Relations N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Senior Vice President of Global Governance, Risk & Compliance N/A
Mr. Darren Patti Group Chief Operating Officer N/A 1972 (52 année)
Dr. David N. Cade M.B.A., M.D., MBBS Group Chief Medical Officer N/A 1969 (55 années)
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, MD, Group CEO & Executive Director 1976 (48 années)
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist

Adresse: Australia, North Melbourne. VIC, 55 Flemington Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://telixpharma.com